The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Corresponding Author
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Chicago, IL 60612
For a full list of contributors, see Appendix 1.
Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Chicago, IL 60612Search for more papers by this authorCorresponding Author
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Chicago, IL 60612
For a full list of contributors, see Appendix 1.
Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Chicago, IL 60612Search for more papers by this authorAbstract
The Movement Disorder Society Task Force for Rating Scales for Parkinson's Disease prepared a critique of the Unified Parkinson's Disease Rating Scale (UPDRS). Strengths of the UPDRS include its wide utilization, its application across the clinical spectrum of PD, its nearly comprehensive coverage of motor symptoms, and its clinimetric properties, including reliability and validity. Weaknesses include several ambiguities in the written text, inadequate instructions for raters, some metric flaws, and the absence of screening questions on several important non-motor aspects of PD. The Task Force recommends that the MDS sponsor the development of a new version of the UPDRS and encourage efforts to establish its clinimetric properties, especially addressing the need to define a Minimal Clinically Relevant Difference and a Minimal Clinically Relevant Incremental Difference, as well as testing its correlation with the current UPDRS. If developed, the new scale should be culturally unbiased and be tested in different racial, gender, and age-groups. Future goals should include the definition of UPDRS scores with confidence intervals that correlate with clinically pertinent designations, “minimal,” “mild,” “moderate,” and “severe” PD. Whereas the presence of non-motor components of PD can be identified with screening questions, a new version of the UPDRS should include an official appendix that includes other, more detailed, and optionally used scales to determine severity of these impairments. © 2003 Movement Disorder Society
REFERENCES
- 1 Fahn S, Elton RL, UPDRS program members. Unified Parkinsons Disease Rating Scale. In: S Fahn, CD Marsden, M Goldstein, DB Calne, editors. Recent developments in Parkinsons disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987. p 153–163.
- 2 Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat 1968; 5: 257–258.
- 3 Duvoisin RC. The evaluation of extrapyramidal disease. In: J de Ajuriaguerra, G Gauthier, editors. Monoamines noyaux gris centraux et syndrome de Parkinson. Paris: Masson; 1971.
- 4 Parkes JD, Zilka KJ, Calver DM, Knill-Jones RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970; 1: 259–262.
- 5 Canter CJ, de la Torre R, Mier M. A method of evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 1961; 133: 143–147.
- 6 Lieberman A, Le Brun Y, Boal D. The use of a dopaminergic receptor stimulating agent (Piribendil ET-495) in Parkinson's disease. In: E Usdin, editor. Advances in biochemical spychopharmacology, Vol 12. New York: Raven Press, 1973; p 415–425.
- 7 Diamond SG, Markham CH, Treciokas LJ. A double-blind comparison of levodopa, madopar and Sinemet in Parkinson's disease. Ann Neurol 1978; 3: 267–272.
- 8 Schwab JF, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: FH Billingham, MC Donaldson, editors. Third Symposium on Parkinson's Disease. Edinburgh: Livingstone; 1968. p 152–157.
- 9 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.
- 10 Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease: a systematic review. Mov Disord 2002; 17: 867–876.
- 11 Mitchell SL, Harper DW, Bhalla R. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology 2000; 19: 100–108.
- 12 Goetz CG, Stebbins GT, Chmura TA, et al. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord 1995; 10: 263–266.
- 13 Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994; 9: 76–83.
- 14 Louis ED, Lynch T, Marder K, et al. Reliability of patient completion of the historical section of the Unified Parkinson's disease Rating Scale. Mov Disord 1996; 11: 185–192.
- 15 Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses' ratings of parkinsonian signs with a modified UPDRS. Neurology 1997; 49: 1580–1587.
- 16 Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119: 585–591.
- 17 Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589–598.
- 18 Rabey JM, Bass H, Bonuccelli U, Brooks D, et al. Evaluation of the short Parkinson's evaluation scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharm 1997; 20: 322–337.
- 19 Hogan T, Grimaldi R, Dingemanse J, et al. The Parkinson's symptom inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects. Parkinson Relat Disord 1999; 5: 93–98.
- 20 Martinez-Martin P, Garcia Urra D, del Ser Quijano T, et al. A new clinical tool for gait evaluation in Parkinson's disease. Clin Neuropharm 1997; 20: 183–194.
- 21 Committee for proprietary medicinal products. Guidance on clinical investigation of medicinal products in the treatment of Parkinson's disease. 2002. Online at http://www.emea.eu.int/pdfs/human/ewp/056395en.pdf.
- 22 Goetz CG, Leurgans S, Raman R et al. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002; 17: 283–288.
- 23 Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2–13.
- 24 Defer GL, Widner H, Marie RM, et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572–84.
- 25 Cubo E, Stebbins GT, Golbe LI, Nieves AV et al. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord 2000; 15: 276–279.
- 26 Ballard C, McKeith I, Burn D, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering with dementia with Lewy bodies. Acta Neurol Scand 1997; 96: 366–371.
- 27 Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176–183.
- 28 Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advance PD. Neurology 1997; 49: 162–168.
- 29 Vieregge P, Stolze H, Klein C, Heberlein I. Gait quantification in Parkinson's disease: locomotor disability and correlation to clinical rating scales. J Neural Transm 1997; 104: 237–248.
- 30 Richards M, Marder K, Cote L, et al. Interrater reliability of the Unified Parkinson's disease Rating Scale motor examination. Mov Disord 1994; 9: 89–91.
- 31 McDermott MP, Jankovic J, Carter J, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Arch Neurol 1995; 52: 565–570.
- 32 Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology 1996; 47 (Suppl. 3): S146–S152.
- 33 Oakes D and the Parkinson Study Group. Progression of early Parkinson's disease until levodopa therapy is required. Neurology 1990; 40( Suppl. 1): 370.
- 34 Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589–1598.
- 35 Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early PD. Neurology 1997; 49: 393–399.
- 36 Tanner CM, Parkinson Study Group. Pramipexole in ethnic minority with Parkinson's disease. Mov Disord 1999; 14 (Suppl. 5): 901.
- 37 Van Hilten JJ, van der Zwan AD, Zwinderman AH, et al. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's disease Rating Scale. Mov Disord 1994; 9: 84–88.
- 38 Stebbins GT, Goetz CG. Factor structure of the Unified Parkinson's disease Rating Scale: Motor Examination section. Mov Disord 1998; 13: 633–636
- 39 Stebbins GT, Goetz CG, Lang AE, et al. Factor analysis of the motor section of the Unified Parkinson's disease Rating Scale during the off-state. Mov Disord 1999; 14: 585589
- 40 Camicioli R, Grossmann SJ, Spencer PS, et al. Discriminating mild parkinsonism: methods for epidemiological research. Mov Disord 2001; 16: 33–40.
- 41 Siderowf A, McDermott M, Kieburtz K, et al. Test-retest reliability of the UPDRS in patients with early Parkinson's disease: results of a multicenter clinical trial. Mov Disord 2002; 17: 758–763.
- 42 Martinez-Martin P, Fontan C, Frades Payo B, et al. Parkinson's disease: quantification of disability based on the Unified Parkinson's disease Rating Scale. Neurologia 2000; 15: 382–387.
- 43 Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes in pain severity. Ann Emerg Med 1996; 27: 485–489.
- 44 Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 2001; 38: 633–638.
- 45 Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. Ann Emerg Med 2001; 38: 639–643.
- 46 Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398–404.
- 47 Price DD, Milling LS, Kirsch I, et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999; 83: 147–156
- 48 Mattocks KM, Horwitz RI. Placebos, Active Control Groups, and the unpredictability Paradox. Biol Psychiatry 2000; 47: 693–698.
- 49 Oremus M, Perrault A, Demers L, et al. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales. J Geriatr Psychiatry Neurol 2000; 13: 197–205.
- 50 Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-based Impression. Neurology 1994; 44: 2315–2321.
- 51 de Bie RMA, de Haan RJ, Nijssen PCG, et al. Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. Lancet 1999; 354: 1665–1669.
- 52 Oertel WH et al. Pergolide versus levodopa monotherapy (PELMOPET) [abstract]. Mov Disord 2000; 15 (Suppl. 3): 4.
- 53 Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–763.
- 54 Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55: 789–794.
- 55 Giladi N, Shabtai H, Benbunan B, et al. The effect of treatment with rivastigmin (Exelon) on cognitive functions of patients with dementia and Parkinson's disease. Neurology 2001; 56: A128.
- 56 Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992; 7: 117–124.
- 57 Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease, phenomenology and pathophysiology. Mov Disord 1994; 9: 2–12.
- 58 Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord 1999; 14: 48–53.
- 59 Prochazka A, Bennett DJ, Stephens MJ, et al. Measurement of rigidity in Parkinson's disease. Mov Disord 1997; 12: 24–32.
- 60 Lang AE. Teaching tape for the motor section of the Unified Parkinson's Disease Rating Scale. Mov Disord 1996; 11: 344–345.
- 61 Marinus J, Ramaker C, Van Hilten JJ, et al. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002; 72: 241–248.
- 62 Martinez-Martin P. Rating scales in Parkinson's disease. In: J Jankovic, E Tolosa, editors. Parkinson's disease and movement disorders, 2nd ed. Baltimore: Williams and Wilkins; 1993. p 281–229.